Spring 2022, blooming flowers
2022 New Year, New Discoveries: Images of scientists conducting experiments and various lab equipment
Rotator commemorating NCI at Frederick's 50th anniversary: black-and-white images of scientists and staff working at the facility and meeting with other scientists
Winter 2021 rotator: images of snow, icicles, and holly at NCI at Frederick
Science in Frederick rotator: images of devices and scientists performing experiments

By Nathalie Walker, Guest Writer Could nanotechnology—the study of tiny matter ranging in size from 1 to 200 nanometers—be the future of cancer treatment? Although it is a relatively new field in cancer research, nanotechnology is not new to everyday life. Have you ever thought about the tennis ball you’ve thrown with your dog at the park and wondered what it is made of? Nanotechnology is used to make the tennis ball stronger.
The Fort Detrick gate hours will change beginning Friday, April 10. The new hours were recently provided by the U.S. Army Garrison (USAG), Fort Detrick. NCI will continue to work with the USAG to address questions that may arise. Note that no changes have been made for facilities outside of the Fort Detrick campus (e.g., the Advanced Technology Research Facility).
By Ashley DeVine, Staff Writer The 19th Annual Spring Research Festival (SRF), sponsored by the National Interagency Confederation for Biological Research (NICBR), will be held May 4–7, at the same location as last year: just off Porter Street, in the back parking lot of Building 1507 (Odom Fitness Center).
By Nancy Parrish, Staff Writer; image by Richard Frederickson, Staff Photographer The additional funding requested for Frederick National Laboratory for Cancer Research (FNLCR) in the Fiscal 2016 Bypass Budget was $25 million, or approximately 3.5 percent of the total additional funding request of $715 million.   Officially called the Professional Judgment Budget, the Bypass Budget is a result of the National Cancer Act of 1971, which authorizes NCI to submit a budget directly to the president, to send to Congress. With a focus on NCI’s research priorities and areas of cancer research
By Frank Blanchard, Staff Writer The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.

Subscribe to Poster

The subscriber's email address.
CAPTCHA

Dates to Note

Upcoming Holidays

Thanksgiving Day
November 28, 2024

Christmas Day
December 25, 2024

New Year's Day
January 1, 2025

Martin Luther King Jr. Day
January 20, 2025

Presidents Day
February 17, 2025

Memorial Day
May 26, 2025

Juneteenth
June 19, 2025

Independence Day
July 4, 2025